Methods. The NHDS is conducted annually by the National Center for Health Statistics, Centers for Disease Control and Prevention, Atlanta, Georgia, to collect demographic and medical information on a sample of hospitalizations from a national probability selection of hospitals in the 50 states and the District of Columbia. 4 All survey procedures involving human subjects and confidentiality were reviewed and approved by the Research Ethics Review Board of the National Center for Health Statistics. The NHDS assigns each sampled hospitalization a maximum of 7 diagnostic codes based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Pulmonary embolism was identified using ICD-9-CM codes 415.1x, 634.6x, 635.6x, 636.6x, 637.6x, 638.6, and 673.2x. The first-listed code is a principal diagnosis. We limited our analysis to a sample of nonnewborn hospitalizations with a first-listed (n = 8990) or an any-listed (n = 14 721) PE diagnosis.
To assess in-hospital deaths with a first-listed or an any-listed PE diagnosis during the study period and to ensure adequate subgroup size, we calculated the annual number of deaths and case-fatality rates for the for linear trend); they were 5.9%, 4.2%, 3.8%, and 2.4%, respectively, for first-listed PE and 11.4%, 7.8%, 7.8%, and 7.1%, respectively, for any-listed PE (Figure) .
Comment.
Because of the scope of this article, we report several overall estimates of in-hospital deaths with a first-listed and an any-listed PE diagnosis in the United States during 2001-2008 that were not available previously. The annual number of deaths ranged from 3600 to 5870 and from 14 870 to 18 560 among hospitalizations with a first-listed PE diagnosis and an any-listed PE diagnosis, respectively. Despite the decline in the overall case-fatality rate of hospitalizations with a PE diagnosis, we did not find a corresponding reduction in the numbers of in-hospital deaths, especially among those with a first-listed PE diagnosis. Although the exact reasons for the decline in case-fatality rates were unknown and may warrant further investigation, the decrease may be multifaceted and could be attributable to a combination of an increased number of PE diagnoses resulting from improved diagnostic techniques together with more effective treatment and fewer complications.
7,8
Regardless of an overall decline in the case-fatality rate in hospitalizations related to PE during the study period, the annual number of in-hospital deaths remains relatively stable, especially for any-listed PE. As the US population is aging, reducing the number of in-hospital deaths from PE and improving patients' quality of life are important clinical and public health goals and pose a formidable challenge for the health care systems. The decline in the case-fatality rate stabilized during the periods of 2005-2006 and 2007-2008 in hospitalizations with any-listed PE. Therefore, our results provide support for identifying and implementing effective preventive strategies among hospitalized patients.
Our research has some limitations. Although we evaluated in-hospital deaths with a diagnosis of PE, PE cases may be underreported because (1) asymptomatic patients with PE and other comorbid conditions might be undiagnosed and (2) a misdiagnosed PE or a PE diagnosis was not made before death occurred. Nonetheless, our study represents an important effort to characterize PE-related mortality burden in US hospitals.
In conclusion, the estimated annual number of inhospital deaths among hospitalizations with a diagnosis of PE remained relatively stable during 2001-2008, despite the decline in the case-fatality rates for the same period. Therefore, PE remains an important clinical and public health concern in the United States. 
